Literature DB >> 27842308

MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.

Tao Xie1, Mengxi Huang, Ye Wang, Liya Wang, Cheng Chen, Xiaoyuan Chu.   

Abstract

Chemotherapy and targeted therapy are the main options for andvanced colorectal cancer (CRC). However, resistance to these therapies is a major challenge in the clinic. Understanding molecular mechanisms and developing effective strategies against the drug resistance are highly desired. Increasing evidence has revealed that microRNAs (miRNAs) are closely linked to drug resistance in CRC. The explosion of knowledge in this field has brought forward new predictive and therapeutic opportunities. In this review, we systemically summarize the roles of miRNAs as regulators, tissue or circulating biomarkers, and therapeutics in the CRC resistance to 5-fluorouracil (5-FU), oxaliplatin and anti-EGFR therapy. We also discuss the potential unsettled issues and future directions concerning these processes.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27842308     DOI: 10.1159/000452525

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  27 in total

1.  miR-200c as a Predictive Biomarker for 5-Fluorouracil Chemosensitivity in Colorectal Cancer.

Authors:  Fatemeh Karimi Dermani; Rezvan Najafi
Journal:  J Gastrointest Cancer       Date:  2018-03

2.  MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line.

Authors:  Yankun Liu; Sugui Han; Yuhui Li; Yan Liu; Di Zhang; Yufeng Li; Jinghua Zhang
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

3.  miRNA-346 promotes proliferation, migration and invasion in liver cancer.

Authors:  Qiang Yu; Xia Yang; Weidong Duan; Chonghui Li; Ying Luo; Shichun Lu
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

4.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 5.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

6.  Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p.

Authors:  Jovana Despotovic; Sandra Dragicevic; Aleksandra Nikolic
Journal:  Cell Biochem Biophys       Date:  2021-04-07       Impact factor: 2.194

7.  Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk.

Authors:  Mercedes Rubio; Mariona Bustamante; Carles Hernandez-Ferrer; Dietmar Fernandez-Orth; Lorena Pantano; Yaris Sarria; Maria Piqué-Borras; Kilian Vellve; Silvia Agramunt; Ramon Carreras; Xavier Estivill; Juan R Gonzalez; Alfredo Mayor
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

8.  ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance.

Authors:  Bruno C Gomes; Mónica Honrado; Ana Armada; Miguel Viveiros; José Rueff; António S Rodrigues
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

Review 9.  MicroRNAs as Biomarkers in Colorectal Cancer.

Authors:  Takaaki Masuda; Naoki Hayashi; Yosuke Kuroda; Shuhei Ito; Hidetoshi Eguchi; Koshi Mimori
Journal:  Cancers (Basel)       Date:  2017-09-13       Impact factor: 6.639

Review 10.  New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications.

Authors:  Ye Wang; Liya Wang; Cheng Chen; Xiaoyuan Chu
Journal:  Mol Cancer       Date:  2018-02-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.